First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer
TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021
Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art prostate cancer imaging tools. The NOBLE Registry is co-supported by Telix and Brussels-based Oncidium Foundation.
ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.